Harold Shlevin Increases Stake in Galectin Therapeutics
Harold Shlevin purchased 7,732 shares of Galectin Therapeutics at $1.23 per share.
Key Points
- Harold Shlevin bought 7,732 shares of Galectin Therapeutics on June 26, 2026, at an average price of $1.23 per share, totaling $9,510.36.
- Shares of Galectin Therapeutics traded near $4.64 on Wednesday, with a market cap of $328.6 million and a 52-week high of $7.13.
- HC Wainwright & Co. reiterated a buy rating for Galectin Therapeutics with an $11 price target on June 23, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Harold Shlevin, a key insider, has increased his stake in Galectin Therapeutics Inc. (NasdaqCM: GALT) by purchasing 7,732 shares. The transaction, completed on June 26, 2026, was at an average price of $1.23 per share, amounting to a total of $9,510.36.
Insider Buying and Selling at Galectin Therapeutics Inc.
In addition to Harold Shlevin's recent purchase, there was notable insider activity at Galectin Therapeutics. On June 29, 2026, Chief Medical Officer Jamil Khurram bought 47,467 shares at $2.50 each. On the same day, Shlevin sold 22,268 shares at $5.04 each under a planned transaction.
Galectin Therapeutics Inc. Stock Up 17.5%
Shares of Galectin Therapeutics traded near $4.64 on Wednesday. The company, with a market capitalization of about $328.6 million, operates in the biotechnology sector. Galectin's stock has a 52-week range between $2.03 and $7.13, with the 50-day moving average at $2.53 and the 200-day moving average at $3.72. The firm's beta is 0.494, indicating lower volatility compared to the broader market.
$GALT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its buy rating for Galectin Therapeutics, setting a price target of $11. This target aligns with the consensus among analysts, who have a mean target price of $11 based on one analyst opinion.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for fibrotic diseases and cancer. The company's leading drug candidate, belapectin, is being tested in Phase 2 studies for patients with advanced fibrosis and cirrhosis. Headquartered in Norcross, Georgia, and led by CEO Joel Lewis, Galectin Therapeutics collaborates with SBH Sciences to develop additional therapies targeting galectin-3.
Bottom Line
Harold Shlevin's recent purchase of Galectin Therapeutics shares adds to the ongoing insider activity at the company. Investors often monitor such transactions for potential insights into insider confidence. However, it's crucial to remember that these insider trades reflect personal strategies and may not indicate future stock performance.
Get Galectin Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $GALT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.